(Q35934100)

11 August 2017

1 reference

title

Beta-blockers in heart failure: are pharmacological differences clinically important? (English)

1 reference

11 August 2017

0 references

1

Marco Metra

1 reference

11 August 2017

2

Livio Dei Cas

1 reference

11 August 2017

4

Philip Poole-Wilson

1 reference

11 August 2017

Andrea di Lenarda

3

1 reference

11 August 2017

1 April 2004

1 reference

11 August 2017

Heart Failure Reviews

1 reference

11 August 2017

9

1 reference

11 August 2017

123-130

1 reference

11 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1023/b:hrev.0000046367.99002.a4

11 August 2017

0 references

cites work

COMET: a proposed mechanism of action to explain the results and concerns about dose

1 reference

12 December 2020

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

1 reference

12 December 2020

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

1 reference

12 December 2020

A rationale for the use of beta-blockers as standard treatment for heart failure

1 reference

12 December 2020

Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic heart failure

1 reference

12 December 2020

beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis

1 reference

12 December 2020

Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

1 reference

12 December 2020

Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure

1 reference

12 December 2020

Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group

1 reference

12 December 2020

A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

1 reference

12 December 2020

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study

1 reference

12 December 2020

Beta-blockade in heart failure: selective versus nonselective agents

1 reference

12 December 2020

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study

1 reference

12 December 2020

Bucindolol displays intrinsic sympathomimetic activity in human myocardium

1 reference

12 December 2020

Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo

1 reference

12 December 2020

Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice

1 reference

12 December 2020

beta Blockade after myocardial infarction: systematic review and meta regression analysis

1 reference

12 December 2020

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

12 December 2020

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

1 reference

12 December 2020

Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure

1 reference

12 December 2020

Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol

1 reference

12 December 2020

Mechanism of action of beta-blocking agents in heart failure

1 reference

12 December 2020

Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group

1 reference

12 December 2020

beta-adrenergic receptor blockade in chronic heart failure

1 reference

12 December 2020

Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

1 reference

12 December 2020

Current guidelines in the pharmacological management of chronic heart failure

1 reference

12 December 2020

Effect of propranolol after acute myocardial infarction in patients with congestive heart failure

1 reference

12 December 2020

Antiadrenergic therapy of chronic heart failure: surprises and new opportunities

1 reference

12 December 2020

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

12 December 2020

Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

1 reference

12 December 2020

Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.

1 reference

12 December 2020

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

1 reference

12 December 2020

Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts

1 reference

12 December 2020

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

1 reference

12 December 2020

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure

1 reference

12 December 2020

Carvedilol: beta-blockade and beyond.

1 reference

12 December 2020

Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.

1 reference

12 December 2020

Adrenergic regulation of cardiac myocyte apoptosis

1 reference

12 December 2020

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

1 reference

12 December 2020

Commentary on the Carvedilol or Metoprolol European Trial (COMET).

1 reference

12 December 2020

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

1 reference

12 December 2020

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

12 December 2020

Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor

1 reference

12 December 2020

Effect of carvedilol on survival in severe chronic heart failure

1 reference

12 December 2020

Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure

1 reference

12 December 2020

Beta blockers in heart failure

1 reference

12 December 2020

Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes

1 reference

12 December 2020

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

12 December 2020

Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial

1 reference

12 December 2020

Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium

1 reference

12 December 2020

The effect of pindolol on the two years mortality after complicated myocardial infarction

1 reference

12 December 2020

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

1 reference

12 December 2020

Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets

1 reference

12 December 2020

A comment on COMET: how to interpret a positive trial?

1 reference

12 December 2020

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

1 reference

12 December 2020

Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death

1 reference

12 December 2020

10.1023/B:HREV.0000046367.99002.A4

Identifiers

DOI

1 reference

PubMed ID

15516860

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15516860